Here's How IDEXX Laboratories is Placed Ahead of Q3 Earnings

IDEXX Laboratories (IDXX) is scheduled to release its Q3 2025 earnings on November 3rd, with consensus estimates forecasting revenues of $1.07 billion, a 9.8% year-over-year increase, and EPS of $3.14, up 12.1%. The company has a strong track record, having beaten EPS estimates in the past four quarters, primarily driven by robust performance in its Companion Animal Group Diagnostics, including new product adoption like the IDEXX inVue Dx Analyzer, alongside growth in its Water and Livestock segments, despite potential macroeconomic headwinds. With a Zacks Rank #2 and a positive Earnings ESP, IDXX is positioned for a potential earnings beat.

Analysis

IDEXX Laboratories (IDXX) is set to release Q3 2025 results on November 3rd, with consensus estimates forecasting revenues of $1.07 billion, a 9.8% year-over-year increase, and EPS of $3.14, up 12.1%. The company has consistently surpassed EPS estimates in the last four quarters, achieving an average surprise of 6.08%, indicating strong operational execution. This consistent performance suggests robust operational execution leading into the current reporting period.

Key growth drivers include the Companion Animal Group (CAG), projected to grow 10% year-over-year, benefiting from higher price realization, expanded test volumes, and the stronger-than-anticipated adoption of the AI-powered IDEXX inVue Dx Analyzer. The Water and Livestock, Poultry and Dairy (LPD) segments are also expected to contribute positively, with anticipated revenue increases of 8.6% and 5% respectively, driven by higher testing volumes and favorable pricing.

While the CAG segment faces potential macroeconomic headwinds and inflationary pressures affecting U.S. same-store clinical visits, Q3 EPS estimates have remained stable at $3.14 for the past 60 days. The company's Zacks Rank #2 and a positive Earnings ESP of +0.23% further suggest a higher probability of an earnings beat, reinforcing analyst confidence despite broader economic concerns.

Key Decisions for Investors

• Investors should closely monitor IDXX's Q3 2025 earnings release for actual revenue and EPS figures, paying particular attention to the performance of the Companion Animal Group and the adoption rates of new diagnostic innovations.
• Evaluate management's forward-looking statements regarding macroeconomic impacts on clinical visits and any shifts in guidance, as these will be crucial for assessing future growth potential.
• Given the company's consistent earnings beat history and positive Zacks model indicators, consider maintaining existing positions while remaining alert to any changes in fundamental drivers or market sentiment.